The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.

The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.

The present invention relates to a novel method for purifying 3,6-anhydro-L-galactose by using microorganisms and provides an effect of improving the production yield of 3,6-anhydro-L-galactose by using microorganisms during purification after enzymatic hydrolysis of agarose or agar.

The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.

The present invention relates to a novel method for purifying 3,6-anhydro-L-galactose by using microorganisms and provides an effect of improving the production yield of 3,6-anhydro-L-galactose by using microorganisms during purification after enzymatic hydrolysis of agarose or agar.

The present invention relates to agarooligosaccharide hydrolase and a method for producing 3,6-anhydro-L-galactose and galactose from agarose by using the same. More specifically, the production yield of 3,6-anhydro-L-galactose and galactose from agarose, that is, the saccharification yield, is improved by using -agarooligosaccharide hydrolase having an agarotriose hydrolytic activity.

The present invention relates to a GH117A -neoagarobiose hydrolase (-NABH) derived from novel agar-degrading bacteria Cellvibrio sp. KY-GH-1 deposited with an accession number KCTC 13629BP, and a method for producing 3,6-anhydro-L-galactose (L-AHG) by using the enzyme. GH117A -neoagarobiose hydrolase derived from novel gar-degrading bacteria Cellvibrio sp. KY-GH-1, of the present invention, uses neoagarobiose as a substrate so as to be capable of producing L-AHG with high efficiency without being significantly limited by temperature and pH ranges, and thus has the excellent effect of being widely usable in the fermentation, food, pharmaceutical industries, and the like.

An engineered bacterium based on Bacillus subtilis is provided, a genome of the engineered bacterium includes a multi-enzyme element, and the multi-enzyme element comprises a class I -agarase element (E1 element), a class II -agarase element (E2 element), and an -neoagaro-diohydrolase element (E3 element). The engineered bacterium integrates agarase genes into the Bacillus subtilis genome, achieving cascade catalysis of agarose to produce active oligosaccharides and monosaccharides, thereby utilizing the biological activity of these active oligosaccharides and monosaccharides to treat intestinal inflammation. An engineered biofilm based on Bacillus subtilis is also provided, which includes the engineered bacterium and its secretions. Furthermore, a living material for multi-enzyme display and treatment of intestinal inflammation in mice is also provided, which includes the engineered bacterium or the engineered biofilm.